Browsing by Author "Galvez-Cardenas, KM"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Patients Age 40 Years and Younger with Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence from Latin America
    (Lippincott Williams and Wilkins, 2023) Martinez-Cordero, H; Peña, C; Schutz, NP; Bove, V; Villano, F; Beltran, C; Donoso, J; Lopez-Vidal, H; Roa-Salinas, MA; Soto, P; Ochoa, P; Duarte, P; Remaggi, G; Corzo, A; Shanley, C; Lopresti, S; Orlando, S; Verri, V; Quiroga, LD; Fantl, D; Ramirez, J; Ospina-Idarraga, A; Idrobo, H; Quintero, G; Gomez, R; Cantu-Martinez, O; Gomez-Almaguer, D; Ruiz-Arguelles, GJ; Galvez-Cardenas, KM; Salazar, LA; Novoa-Caicedo, I; Fuentes-Lacouture, MC; Spirko, P; Arbelaez, MI; Pereira, M; Valdes, J; Vasquez, J; Von-Glasenapp, A; Riva, E
    PURPOSEMultiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce.PATIENTS AND METHODSWe analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older.RESULTSThere were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Of the patients age 40 years or younger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival.CONCLUSIONIn conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly. © American Society of Clinical Oncology.
  • Thumbnail Image
    Publication
    Patrones de tratamiento y resultados clínicos en pacientes con leucemia mieloide aguda no elegibles para quimioterapia de inducción intensiva: estudio de vida real en América Latina
    (Universidad de Antioquia, 2023) Galvez-Cardenas, KM; Enciso-Olivera, LJ; Samanez-Figari, CA; Quintana-Truyenque, S; Castillo-Rios, BA; Quintero-Vega, GE; Arrieta-Lopez, E; Pinto-Gomez, AJ; Aruachan-Vesga, S; Duran-Sanchez, MI; Espino-Lopez, G
    Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemothera-py; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the results of the different treatment strategies within this context. Methodology. This is a longitu-dinal, descriptive, retrospective study of a cohort of Latin American patients with AML not eligible for intensive induction chemotherapy, treated with low-intensity chemotherapy or with the best supportive care alone between January 1, 2015, to December 31, 2018. Results. Of a total of 125 patients (median age 74.8 years), the majority received low-intensity chemotherapy (78.4%). The median time in months of overall survival (9.2), progression-free survival (4.8), and time to treatment failure (3.8) were longer in patients receiving hypomethylating agents. Additionally, better results were observed with low-intensity chemotherapy (complete response 11.2% and stable disease 17.3%) compared to the best supportive care alone. Conclu-sion. We deliver a real-world standpoint of Latin American patients with AML who are not eligible for intensive induction chemotherapy. Our findings pave the first steps of the way to describe, understand, and support informed decision-making processes in our region.